Are you over 18 and want to see adult content?
More Annotations
![A complete backup of cavallopoint.com](https://www.archivebay.com/archive2/49ce2f7d-5bdc-41b5-88a0-a35e3ec65c31.png)
A complete backup of cavallopoint.com
Are you over 18 and want to see adult content?
![A complete backup of esthe-ranking.jp](https://www.archivebay.com/archive2/93f8676d-f3e8-4ea5-b4ce-9f6af3b82700.png)
A complete backup of esthe-ranking.jp
Are you over 18 and want to see adult content?
![A complete backup of raptorsrepublic.com](https://www.archivebay.com/archive2/3879c4a4-f398-4fa1-ac49-b689568696d1.png)
A complete backup of raptorsrepublic.com
Are you over 18 and want to see adult content?
![A complete backup of clermont-ferrand.fr](https://www.archivebay.com/archive2/28316451-03b3-4431-ab85-421b04f43156.png)
A complete backup of clermont-ferrand.fr
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of https://echo24.de](https://www.archivebay.com/archive6/images/50cad704-98a1-41cc-9167-b0f8def91628.png)
A complete backup of https://echo24.de
Are you over 18 and want to see adult content?
![A complete backup of https://the-bitcoinpro.com](https://www.archivebay.com/archive6/images/96623d00-088f-49fc-b894-1fd9f85041b6.png)
A complete backup of https://the-bitcoinpro.com
Are you over 18 and want to see adult content?
![A complete backup of https://frontx.com](https://www.archivebay.com/archive6/images/113267e6-55e7-45e9-bb9a-3170cc261134.png)
A complete backup of https://frontx.com
Are you over 18 and want to see adult content?
![A complete backup of https://caregiveraction.org](https://www.archivebay.com/archive6/images/0a77c8ac-4f43-48d0-b91e-7cf033c8da92.png)
A complete backup of https://caregiveraction.org
Are you over 18 and want to see adult content?
![A complete backup of https://thenewsguard.com](https://www.archivebay.com/archive6/images/0cc87987-3e36-4a6c-838d-0acf45c68983.png)
A complete backup of https://thenewsguard.com
Are you over 18 and want to see adult content?
![A complete backup of https://oar-mures.ro](https://www.archivebay.com/archive6/images/16e81a65-3196-4601-8ba3-8fdc532c0492.png)
A complete backup of https://oar-mures.ro
Are you over 18 and want to see adult content?
![A complete backup of https://gardensite.co.uk](https://www.archivebay.com/archive6/images/c800305a-d0ee-47c9-ac28-03163c507e84.png)
A complete backup of https://gardensite.co.uk
Are you over 18 and want to see adult content?
![A complete backup of https://advanceadapters.com](https://www.archivebay.com/archive6/images/11b9be2a-1306-48cd-9e1e-5763763a0b29.png)
A complete backup of https://advanceadapters.com
Are you over 18 and want to see adult content?
![A complete backup of https://sterlitamak.ru](https://www.archivebay.com/archive6/images/4876c64e-fef6-459d-9618-2d57e42e1f7b.png)
A complete backup of https://sterlitamak.ru
Are you over 18 and want to see adult content?
![A complete backup of https://incontext.pl](https://www.archivebay.com/archive6/images/8ce0e833-d4ef-42a3-ba03-8b33639ac744.png)
A complete backup of https://incontext.pl
Are you over 18 and want to see adult content?
![A complete backup of https://bluebookofpianos.com](https://www.archivebay.com/archive6/images/8ec061c9-cc7b-440f-93fb-d0bf30418ea5.png)
A complete backup of https://bluebookofpianos.com
Are you over 18 and want to see adult content?
![A complete backup of https://avwines.com](https://www.archivebay.com/archive6/images/fca58cdb-2c06-4b89-95fb-4daa224882fe.png)
A complete backup of https://avwines.com
Are you over 18 and want to see adult content?
Text
BENEVOLENTAI
BenevolentAI is the global leader in the development and application of artificial intelligence for drug discovery and development. We fuse science and technology to accelerate the discovery of more effective medicines for patients.BENEVOLENTAI
At Benevolent we build our AI and machine learning tools in the service of science, with the goal of providing scientists with augmented capabilities to discover, develop and test new medicines to tackle diseases that currently have no cure and discover new life-changing treatments. PARTNERING - BENEVOLENT Maximise the opportunity to find novel drug targets for disease areas of interest, working with our cross-functional team of expert technologists, data scientists and drug discovery scientists.BENEVOLENTAI
De novo design seeks to generate molecules with required property profiles by virtual design-make-test cycles. With the emergence of deep learning and neural generative models in many application areas, models for molecular design based on neural networks appeared recently and show promising results. BENEVOLENTAI ANNOUNCES FIRST PATIENT DOSED IN ITS ATOPIC BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat AtopicDermatitis.
MARK DAVIES
Mark Davies is the SVP Informatics and Data at BenevolentAI. He has over 15 years of experience working on biomedical data representation, data analysis and application development.BENEVOLENTAI
BenevolentAI is the global leader in the development and application of artificial intelligence for drug discovery and development. We fuse science and technology to accelerate the discovery of more effective medicines for patients.BENEVOLENTAI
At Benevolent we build our AI and machine learning tools in the service of science, with the goal of providing scientists with augmented capabilities to discover, develop and test new medicines to tackle diseases that currently have no cure and discover new life-changing treatments. PARTNERING - BENEVOLENT Maximise the opportunity to find novel drug targets for disease areas of interest, working with our cross-functional team of expert technologists, data scientists and drug discovery scientists.BENEVOLENTAI
De novo design seeks to generate molecules with required property profiles by virtual design-make-test cycles. With the emergence of deep learning and neural generative models in many application areas, models for molecular design based on neural networks appeared recently and show promising results. BENEVOLENTAI ANNOUNCES FIRST PATIENT DOSED IN ITS ATOPIC BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat AtopicDermatitis.
MARK DAVIES
Mark Davies is the SVP Informatics and Data at BenevolentAI. He has over 15 years of experience working on biomedical data representation, data analysis and application development. BENEVOLENTAI DRUG PROGRAMMES BenevolentAI has developed several drug programmes, extending from early discovery through to the clinic focusing on disease areas with high unmet medical need. BENEVOLENTAI’S PLATFORM-DERIVED HYPOTHESIS FOR COVID-19 Media enquiries. Rajin Kang | rajin.kang@benevolent.ai . Note to editors: Baricitinib is approved for the treatment of rheumatoid arthritis and other diseases. It is administered orally and has been used to treat COVID-19 patients in more than 14 clinical trials worldwide including the randomised clinical trials by the NIAID andEli Lilly.
NEWS - BENEVOLENT
Get the latest news and updates from BenevolentAI on our drug and research programmes, collaborations, investments and events.OFFICE MANAGER
The Office Manager will organize and coordinate office administration and procedures, in order to ensure organizational effectiveness, efficiency and safety. BENEVOLENTAI AND ASTRAZENECA ACHIEVE COLLABORATION BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company’sportfolio.
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY There has been a great deal of hype surrounding the resurgence of Artificial Intelligence and Machine Learning. This commentary was published in Future Medicinal Chemistry as a brief overview of the AI and ML domains, their relevance in different aspects of drug discovery and, importantly, reflecting on managing expectations from differentquarters.
PROGRAMME MANAGER
Programme Manager The Company. BenevolentAI unites technology with human intelligence to re-engineer drug discovery and deliver life-changing medicines. BENEVOLENTAI ANNOUNCES AGREEMENT WITH LEADING HEALTHCARE BenevolentAI has collaborated with Novartis Global Drug Development on an initial project in oncology, which will see the application of our AI and machine learning technology to stratify patients to more precisely target medicines.ANNE PHELAN
Anne is Chief Scientific Officer, Head of Preclinical Development and Site Head for the Benevolent Cambridge Laboratories. Anne is responsible for driving the early AI augmented discovery portfolio through Lead Optimisation to delivery of pre-clinical candidate drugmolecules.
WOMEN IN BIOTECH WITH PEJU OSHISANYA Peju Oshisanya will join three other exceptional speakers from the biotech industry to discuss their personal journeys through research and biotechnology, also delving into their expertise on AI on how we can adopt this emerging technology to the benefit of biomedicalresearch and
BENEVOLENTAI
BenevolentAI is the global leader in the development and application of artificial intelligence for drug discovery and development. We fuse science and technology to accelerate the discovery of more effective medicines for patients.BENEVOLENTAI
At Benevolent we build our AI and machine learning tools in the service of science, with the goal of providing scientists with augmented capabilities to discover, develop and test new medicines to tackle diseases that currently have no cure and discover new life-changing treatments. PARTNERING - BENEVOLENT Partner with us to develop innovative therapeutics. We work with the world’s leading pharmaceutical companies, biotechs and academic research institutions to unlock biological insights and develop novel drug treatments. COLLABORATIONS. Combining expertise to transform and accelerate drug discovery and development. BENEVOLENTAI’S PLATFORM-DERIVED HYPOTHESIS FOR COVID-19 →Baricitinib in combination with remdesivir reduces the recovery time in hospitalised patients with COVID-19 → Data validates AI-derived hypothesis for treatment first published by BenevolentAI in The Lancet on February 4, 2020 BENEVOLENTAI ANNOUNCES FIRST PATIENT DOSED IN ITS ATOPIC BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis. London, 11 February 2020 - This significant milestone seesa best
BENEVOLENTAI ANNOUNCES $90 MILLION INVESTMENT FROM TEMASEK New capital will accelerate scientific and product innovation and drive further scale of drug discovery and development platform. London, September 17 2019: BenevolentAI, the leader in the creation and application of AI and machine learning to transform the way medicines are discovered and developed, today announces that it has raised $90 million from Temasek, a Singapore-headquarteredMARK DAVIES
Mark Davies is the SVP Informatics and Data at BenevolentAI. He has over 15 years of experience working on biomedical data representation, data analysis and application development.DAVE MICHALOVICH
Prior to joining BenevolentAI Dave was a Senior Scientific Director at GSK where he led discovery teams in the Adaptive Immunity Research Unit and Respiratory TA, and has previously held positions at Syntaxin, Curidium Medica, Inpharmatica and Smithkline Beecham. EVE BERRY | BENEVOLENTAI Eve Berry is responsible for the financial operations function across the Group, which includes all financial operations, cash management, compliance, tax and statutory reporting. Eve is chartered accountant, an alumni of Deloittes, and has held a number of finance leadership positions across international healthcare and other business toTRECILLA LOBO
Trecilla is the SVP, People. She is responsible for all things people, including Talent acquisition, people experience and culture at BAI, people analytics, as well as office and facilities. Trecilla has over 20 years experience in senior HR roles in digital media, pharmaceutical and technology companies, including Trader Media Group(which was
BENEVOLENTAI
BenevolentAI is the global leader in the development and application of artificial intelligence for drug discovery and development. We fuse science and technology to accelerate the discovery of more effective medicines for patients.BENEVOLENTAI
At Benevolent we build our AI and machine learning tools in the service of science, with the goal of providing scientists with augmented capabilities to discover, develop and test new medicines to tackle diseases that currently have no cure and discover new life-changing treatments. PARTNERING - BENEVOLENT Partner with us to develop innovative therapeutics. We work with the world’s leading pharmaceutical companies, biotechs and academic research institutions to unlock biological insights and develop novel drug treatments. COLLABORATIONS. Combining expertise to transform and accelerate drug discovery and development. BENEVOLENTAI’S PLATFORM-DERIVED HYPOTHESIS FOR COVID-19 →Baricitinib in combination with remdesivir reduces the recovery time in hospitalised patients with COVID-19 → Data validates AI-derived hypothesis for treatment first published by BenevolentAI in The Lancet on February 4, 2020 BENEVOLENTAI ANNOUNCES FIRST PATIENT DOSED IN ITS ATOPIC BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis. London, 11 February 2020 - This significant milestone seesa best
BENEVOLENTAI ANNOUNCES $90 MILLION INVESTMENT FROM TEMASEK New capital will accelerate scientific and product innovation and drive further scale of drug discovery and development platform. London, September 17 2019: BenevolentAI, the leader in the creation and application of AI and machine learning to transform the way medicines are discovered and developed, today announces that it has raised $90 million from Temasek, a Singapore-headquarteredMARK DAVIES
Mark Davies is the SVP Informatics and Data at BenevolentAI. He has over 15 years of experience working on biomedical data representation, data analysis and application development.DAVE MICHALOVICH
Prior to joining BenevolentAI Dave was a Senior Scientific Director at GSK where he led discovery teams in the Adaptive Immunity Research Unit and Respiratory TA, and has previously held positions at Syntaxin, Curidium Medica, Inpharmatica and Smithkline Beecham. EVE BERRY | BENEVOLENTAI Eve Berry is responsible for the financial operations function across the Group, which includes all financial operations, cash management, compliance, tax and statutory reporting. Eve is chartered accountant, an alumni of Deloittes, and has held a number of finance leadership positions across international healthcare and other business toTRECILLA LOBO
Trecilla is the SVP, People. She is responsible for all things people, including Talent acquisition, people experience and culture at BAI, people analytics, as well as office and facilities. Trecilla has over 20 years experience in senior HR roles in digital media, pharmaceutical and technology companies, including Trader Media Group(which was
BENEVOLENTAI’S PLATFORM-DERIVED HYPOTHESIS FOR COVID-19 Media enquiries. Rajin Kang | rajin.kang@benevolent.ai . Note to editors: Baricitinib is approved for the treatment of rheumatoid arthritis and other diseases. It is administered orally and has been used to treat COVID-19 patients in more than 14 clinical trials worldwide including the randomised clinical trials by the NIAID andEli Lilly.
NEWS - BENEVOLENT
News. FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI. BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph. Nov 20, 2020. BENEVOLENTAI DRUG PROGRAMMES Drug Development Licensing partnerships. Using the Benevolent Platform, we are actively building out our own pipeline. Through strategic licensing partnerships, we work with larger pharma companies with deep and global capabilities in late stage development and commercialisation to deliver innovative medicines to BENEVOLENTAI AND ASTRAZENECA ACHIEVE COLLABORATION BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company’sportfolio.
OFFICE MANAGER
The Office Manager will organize and coordinate office administration and procedures, in order to ensure organizational effectiveness, efficiency and safety. MEET THE BENEVOLENTAI TEAM AT ICML 2020 Meet the BenevolentAI team at ICML 2020. Jul 12, 2020. Home NEWS Events. Meet the BenevolentAI team at ICML 2020. We are pleased to announce that BenevolentAI is sponsoring the virtual ICML 2020 conference from the 12th to 18th of July. You can find our team on the EXPO day and Women in Machine Learning workshop - we hope to meet youthere.
ANNE PHELAN
Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stagedevelopment.
TOM HOLGATE
Tom is the Group Finance Director at BenevolentAI. He is responsible for all financial aspects of the Group including operational, reporting, strategy, planning and forecasting, transaction support andinvestor relations.
WOMEN IN BIOTECH WITH PEJU OSHISANYA Peju Oshisanya will join three other exceptional speakers from the biotech industry to discuss their personal journeys through research and biotechnology, also delving into their expertise on AI on how we can adopt this emerging technology to the benefit of biomedicalresearch and
EVE BERRY | BENEVOLENTAI Eve Berry is responsible for the financial operations function across the Group, which includes all financial operations, cash management, compliance, tax and statutory reporting. Eve is chartered accountant, an alumni of Deloittes, and has held a number of finance leadership positions across international healthcare and other business toBENEVOLENTAI
BenevolentAI is the global leader in the development and application of artificial intelligence for drug discovery and development. We fuse science and technology to accelerate the discovery of more effective medicines for patients.BENEVOLENTAI
At Benevolent we build our AI and machine learning tools in the service of science, with the goal of providing scientists with augmented capabilities to discover, develop and test new medicines to tackle diseases that currently have no cure and discover new life-changing treatments. PARTNERING - BENEVOLENT Partner with us to develop innovative therapeutics. We work with the world’s leading pharmaceutical companies, biotechs and academic research institutions to unlock biological insights and develop novel drug treatments. COLLABORATIONS. Combining expertise to transform and accelerate drug discovery and development. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY There has been a great deal of hype surrounding the resurgence of Artificial Intelligence and Machine Learning. This commentary was published in Future Medicinal Chemistry as a brief overview of the AI and ML domains, their relevance in different aspects of drug discovery and, importantly, reflecting on managing expectations from differentquarters.
BENEVOLENTAI ANNOUNCES $90 MILLION INVESTMENT FROM TEMASEK New capital will accelerate scientific and product innovation and drive further scale of drug discovery and development platform. London, September 17 2019: BenevolentAI, the leader in the creation and application of AI and machine learning to transform the way medicines are discovered and developed, today announces that it has raised $90 million from Temasek, a Singapore-headquarteredMARK DAVIES
Mark Davies is the SVP Informatics and Data at BenevolentAI. He has over 15 years of experience working on biomedical data representation, data analysis and application development.TOM HOLGATE
Tom is the Group Finance Director at BenevolentAI. He is responsible for all financial aspects of the Group including operational, reporting, strategy, planning and forecasting, transaction support andinvestor relations.
ANNE PHELAN
Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stagedevelopment.
EVE BERRY | BENEVOLENTAI Eve Berry is responsible for the financial operations function across the Group, which includes all financial operations, cash management, compliance, tax and statutory reporting. Eve is chartered accountant, an alumni of Deloittes, and has held a number of finance leadership positions across international healthcare and other business toTRECILLA LOBO
Trecilla is the SVP, People. She is responsible for all things people, including Talent acquisition, people experience and culture at BAI, people analytics, as well as office and facilities. Trecilla has over 20 years experience in senior HR roles in digital media, pharmaceutical and technology companies, including Trader Media Group(which was
BENEVOLENTAI
BenevolentAI is the global leader in the development and application of artificial intelligence for drug discovery and development. We fuse science and technology to accelerate the discovery of more effective medicines for patients.BENEVOLENTAI
At Benevolent we build our AI and machine learning tools in the service of science, with the goal of providing scientists with augmented capabilities to discover, develop and test new medicines to tackle diseases that currently have no cure and discover new life-changing treatments. PARTNERING - BENEVOLENT Partner with us to develop innovative therapeutics. We work with the world’s leading pharmaceutical companies, biotechs and academic research institutions to unlock biological insights and develop novel drug treatments. COLLABORATIONS. Combining expertise to transform and accelerate drug discovery and development. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY There has been a great deal of hype surrounding the resurgence of Artificial Intelligence and Machine Learning. This commentary was published in Future Medicinal Chemistry as a brief overview of the AI and ML domains, their relevance in different aspects of drug discovery and, importantly, reflecting on managing expectations from differentquarters.
BENEVOLENTAI ANNOUNCES $90 MILLION INVESTMENT FROM TEMASEK New capital will accelerate scientific and product innovation and drive further scale of drug discovery and development platform. London, September 17 2019: BenevolentAI, the leader in the creation and application of AI and machine learning to transform the way medicines are discovered and developed, today announces that it has raised $90 million from Temasek, a Singapore-headquarteredMARK DAVIES
Mark Davies is the SVP Informatics and Data at BenevolentAI. He has over 15 years of experience working on biomedical data representation, data analysis and application development.TOM HOLGATE
Tom is the Group Finance Director at BenevolentAI. He is responsible for all financial aspects of the Group including operational, reporting, strategy, planning and forecasting, transaction support andinvestor relations.
ANNE PHELAN
Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stagedevelopment.
EVE BERRY | BENEVOLENTAI Eve Berry is responsible for the financial operations function across the Group, which includes all financial operations, cash management, compliance, tax and statutory reporting. Eve is chartered accountant, an alumni of Deloittes, and has held a number of finance leadership positions across international healthcare and other business toTRECILLA LOBO
Trecilla is the SVP, People. She is responsible for all things people, including Talent acquisition, people experience and culture at BAI, people analytics, as well as office and facilities. Trecilla has over 20 years experience in senior HR roles in digital media, pharmaceutical and technology companies, including Trader Media Group(which was
NEWS - BENEVOLENT
News. Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%. The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19patient
BENEVOLENTAI
We’re tackling one of the most challenging and urgent problems facing humanity, and we’re looking for exceptional people to join us. We are fusing technology with human intelligence to develop new medicines that preserve human life. We focus our skills and energy on our mission, every day and in everything we do, from each hiringdecision
BENEVOLENTAI DRUG PROGRAMMES Drug Development Licensing partnerships. Using the Benevolent Platform, we are actively building out our own pipeline. Through strategic licensing partnerships, we work with larger pharma companies with deep and global capabilities in late stage development and commercialisation to deliver innovative medicines to BENEVOLENTAI AND ASTRAZENECA ACHIEVE COLLABORATION BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company’sportfolio.
ANNE PHELAN
Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stagedevelopment.
MEET THE BENEVOLENTAI TEAM AT ICML 2020 Meet the BenevolentAI team at ICML 2020. Jul 12, 2020. Home NEWS Events. Meet the BenevolentAI team at ICML 2020. We are pleased to announce that BenevolentAI is sponsoring the virtual ICML 2020 conference from the 12th to 18th of July. You can find our team on the EXPO day and Women in Machine Learning workshop - we hope to meet youthere.
TRECILLA LOBO
Trecilla is the SVP, People. She is responsible for all things people, including Talent acquisition, people experience and culture at BAI, people analytics, as well as office and facilities. Trecilla has over 20 years experience in senior HR roles in digital media, pharmaceutical and technology companies, including Trader Media Group(which was
WOMEN IN BIOTECH WITH PEJU OSHISANYA Peju Oshisanya will join three other exceptional speakers from the biotech industry to discuss their personal journeys through research and biotechnology, also delving into their expertise on AI on how we can adopt this emerging technology to the benefit of biomedicalresearch and
PEOPLE COORDINATOR
The Role. BenevolentAI are excited to have a fantastic opportunity to join our team on a full-time basis based in our modern spec offices in London. The People Coordinator supports the ongoing business partnering approach of the People function by delivering comprehensive operational HR services across all BenevolentAI locations.DAVE MICHALOVICH
Prior to joining BenevolentAI Dave was a Senior Scientific Director at GSK where he led discovery teams in the Adaptive Immunity Research Unit and Respiratory TA, and has previously held positions at Syntaxin, Curidium Medica, Inpharmatica and Smithkline Beecham.BENEVOLENTAI
BenevolentAI is the global leader in the development and application of artificial intelligence for drug discovery and development. We fuse science and technology to accelerate the discovery of more effective medicines for patients.BENEVOLENTAI
At Benevolent we build our AI and machine learning tools in the service of science, with the goal of providing scientists with augmented capabilities to discover, develop and test new medicines to tackle diseases that currently have no cure and discover new life-changing treatments. PARTNERING - BENEVOLENT Partner with us to develop innovative therapeutics. We work with the world’s leading pharmaceutical companies, biotechs and academic research institutions to unlock biological insights and develop novel drug treatments. COLLABORATIONS. Combining expertise to transform and accelerate drug discovery and development. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY There has been a great deal of hype surrounding the resurgence of Artificial Intelligence and Machine Learning. This commentary was published in Future Medicinal Chemistry as a brief overview of the AI and ML domains, their relevance in different aspects of drug discovery and, importantly, reflecting on managing expectations from differentquarters.
BENEVOLENTAI ANNOUNCES $90 MILLION INVESTMENT FROM TEMASEK New capital will accelerate scientific and product innovation and drive further scale of drug discovery and development platform. London, September 17 2019: BenevolentAI, the leader in the creation and application of AI and machine learning to transform the way medicines are discovered and developed, today announces that it has raised $90 million from Temasek, a Singapore-headquarteredMARK DAVIES
Mark Davies is the SVP Informatics and Data at BenevolentAI. He has over 15 years of experience working on biomedical data representation, data analysis and application development.TOM HOLGATE
Tom is the Group Finance Director at BenevolentAI. He is responsible for all financial aspects of the Group including operational, reporting, strategy, planning and forecasting, transaction support andinvestor relations.
ANNE PHELAN
Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stagedevelopment.
EVE BERRY | BENEVOLENTAI Eve Berry is responsible for the financial operations function across the Group, which includes all financial operations, cash management, compliance, tax and statutory reporting. Eve is chartered accountant, an alumni of Deloittes, and has held a number of finance leadership positions across international healthcare and other business toTRECILLA LOBO
Trecilla is the SVP, People. She is responsible for all things people, including Talent acquisition, people experience and culture at BAI, people analytics, as well as office and facilities. Trecilla has over 20 years experience in senior HR roles in digital media, pharmaceutical and technology companies, including Trader Media Group(which was
BENEVOLENTAI
BenevolentAI is the global leader in the development and application of artificial intelligence for drug discovery and development. We fuse science and technology to accelerate the discovery of more effective medicines for patients.BENEVOLENTAI
At Benevolent we build our AI and machine learning tools in the service of science, with the goal of providing scientists with augmented capabilities to discover, develop and test new medicines to tackle diseases that currently have no cure and discover new life-changing treatments. PARTNERING - BENEVOLENT Partner with us to develop innovative therapeutics. We work with the world’s leading pharmaceutical companies, biotechs and academic research institutions to unlock biological insights and develop novel drug treatments. COLLABORATIONS. Combining expertise to transform and accelerate drug discovery and development. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY There has been a great deal of hype surrounding the resurgence of Artificial Intelligence and Machine Learning. This commentary was published in Future Medicinal Chemistry as a brief overview of the AI and ML domains, their relevance in different aspects of drug discovery and, importantly, reflecting on managing expectations from differentquarters.
BENEVOLENTAI ANNOUNCES $90 MILLION INVESTMENT FROM TEMASEK New capital will accelerate scientific and product innovation and drive further scale of drug discovery and development platform. London, September 17 2019: BenevolentAI, the leader in the creation and application of AI and machine learning to transform the way medicines are discovered and developed, today announces that it has raised $90 million from Temasek, a Singapore-headquarteredMARK DAVIES
Mark Davies is the SVP Informatics and Data at BenevolentAI. He has over 15 years of experience working on biomedical data representation, data analysis and application development.TOM HOLGATE
Tom is the Group Finance Director at BenevolentAI. He is responsible for all financial aspects of the Group including operational, reporting, strategy, planning and forecasting, transaction support andinvestor relations.
ANNE PHELAN
Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stagedevelopment.
EVE BERRY | BENEVOLENTAI Eve Berry is responsible for the financial operations function across the Group, which includes all financial operations, cash management, compliance, tax and statutory reporting. Eve is chartered accountant, an alumni of Deloittes, and has held a number of finance leadership positions across international healthcare and other business toTRECILLA LOBO
Trecilla is the SVP, People. She is responsible for all things people, including Talent acquisition, people experience and culture at BAI, people analytics, as well as office and facilities. Trecilla has over 20 years experience in senior HR roles in digital media, pharmaceutical and technology companies, including Trader Media Group(which was
NEWS - BENEVOLENT
News. Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%. The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19patient
BENEVOLENTAI
We’re tackling one of the most challenging and urgent problems facing humanity, and we’re looking for exceptional people to join us. We are fusing technology with human intelligence to develop new medicines that preserve human life. We focus our skills and energy on our mission, every day and in everything we do, from each hiringdecision
BENEVOLENTAI DRUG PROGRAMMES Drug Development Licensing partnerships. Using the Benevolent Platform, we are actively building out our own pipeline. Through strategic licensing partnerships, we work with larger pharma companies with deep and global capabilities in late stage development and commercialisation to deliver innovative medicines to BENEVOLENTAI AND ASTRAZENECA ACHIEVE COLLABORATION BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company’sportfolio.
ANNE PHELAN
Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stagedevelopment.
MEET THE BENEVOLENTAI TEAM AT ICML 2020 Meet the BenevolentAI team at ICML 2020. Jul 12, 2020. Home NEWS Events. Meet the BenevolentAI team at ICML 2020. We are pleased to announce that BenevolentAI is sponsoring the virtual ICML 2020 conference from the 12th to 18th of July. You can find our team on the EXPO day and Women in Machine Learning workshop - we hope to meet youthere.
TRECILLA LOBO
Trecilla is the SVP, People. She is responsible for all things people, including Talent acquisition, people experience and culture at BAI, people analytics, as well as office and facilities. Trecilla has over 20 years experience in senior HR roles in digital media, pharmaceutical and technology companies, including Trader Media Group(which was
WOMEN IN BIOTECH WITH PEJU OSHISANYA Peju Oshisanya will join three other exceptional speakers from the biotech industry to discuss their personal journeys through research and biotechnology, also delving into their expertise on AI on how we can adopt this emerging technology to the benefit of biomedicalresearch and
PEOPLE COORDINATOR
The Role. BenevolentAI are excited to have a fantastic opportunity to join our team on a full-time basis based in our modern spec offices in London. The People Coordinator supports the ongoing business partnering approach of the People function by delivering comprehensive operational HR services across all BenevolentAI locations.DAVE MICHALOVICH
Prior to joining BenevolentAI Dave was a Senior Scientific Director at GSK where he led discovery teams in the Adaptive Immunity Research Unit and Respiratory TA, and has previously held positions at Syntaxin, Curidium Medica, Inpharmatica and Smithkline Beecham. OUr APPROACHWHAT WE DO WHY IT MATTERSRESEARCH
PIPELINEDRUG PROGRAMMES COVID-19 PARTNERINGCOLLABORATIONS LICENSING ABOUT USOUR TEAM LEADERSHIP JOIN USCAREERS JOBS INTERNSHIPSCULTURE BLOG
NEws
At BenevolentAI, your privacy and trust are important to us. We use cookies to personalise content, provide social media features and to analyse our websites for better performance. Information about your use of our website may be shared with our social media and analytics partners from time to time. Detailed understanding of cookies and how to control their placement on your system can be found in our PrivacyPolicy Got It
At BenevolentAI, your privacy and trust are important to us. We use cookies to personalise content, provide social media features and to analyse our websites for better performance. Information about your use of our website may be shared with our social media and analytics partners from time to time. Detailed understanding of cookies and how to control their placement on your system can be found in our PrivacyPolicy Got It
HUMAN LIFE IS PRECIOUS. WE HAVE NEVER BEEN MORE AWARE OF ITS FRAGILITY. Today there are thousands of diseases that have no treatment and millions are suffering with no hope for a cure. PATIENTS DESERVEBETTER.
WHAT WE DO
WE ENVISION A WORLD WHERE NO DISEASE GOES UNTREATED. This is not a world that will emerge, it is a world we must create. The exponential growth and availability of biomedical data present new opportunities to fuse science and technology and re-engineer drug discovery and development. THIS IS WHAT WE DO.OUR MISSION
DECODING DISEASE TO UNDERSTAND ITS UNDERLYING CAUSES. Every day there are thousands of scientific papers published, hundreds of millions of medical records created, vast amounts of data collected and research completed. Our AI and machine learning models empower scientists to make sense of all of that information to decipher the complex code underlying human biology.DRUG PROGRAMMES
OUR WORK TO DECODE COVID-19. Responding to the global health crisis, we turned our AI platform toward identifying existing drugs that could be used to treat the novel coronavirus. Our research led to a clinical trial with Eli Lilly and the US National Institute for Allergies and Infectious Diseases.find out more
WE ENVISION A WORLD WHERE NO DISEASE GOES UNTREATED This is not a world that will emerge, it is a world we must create. The exponential growth and availability of biomedical data present new opportunities to fuse science and technology and re-engineer drug discovery and development. This is what we do. WE DECODE DISEASE TO UNDERSTAND ITS UNDERLYING CAUSES Every day there are thousands of scientific papers published, hundreds of millions of medical records created, vast amounts of data collected and research completed. Our machine learning models and algorithms empower scientists to make sense of all of that information. OUR RESEARCH TO FIND A POTENTIAL TREATMENT FOR COVID-19 Responding to the global health crisis, we turned our AI platform toward identifying existing drugs that could be used to treat the novel coronavirus. Our research led to a clinical trial with Eli Lilly and the US National Institute for Allergies and Infectious Diseases.BEcause it matters.
THE BENEVOLENT PLATFORM® Human intelligence and technology united to re-engineer drug discovery and deliver life-changing medicines. KNOWLEDGE & REASONING Our expanding biomedical knowledge base of contextualised machine-curated relationships and proprietary insights represents what is known and can be inferred about a disease. TARGET IDENTIFICATION Data-driven Target ID built on our machine learning models selects and validates the highest quality, hypotheses for novel drug targets.PRECISION MEDICINE
Applied machine learning models enable scientists to determine the right mechanism to modulate, and identify patient endotypes more likely to respond to treatment.MOLECULAR DESIGN
AI-augmented models empower our chemists to evaluate millions of molecular structures, generate drug-like molecules and design better drugs in fewer cycles.WHAT WE DO
JOIN FORCES WITH US
BY WORKING TOGETHER, PROFOUND DISCOVERIES ARE MADEPartner with us
Our Benevolent people MISSION-DRIVEN TO PRESERVE HUMAN LIFE At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment.01
ABOUT US
02
PURPOSE
03
Join us
_"The fragile nature of life and health has never been more apparent, but the partnership of human and artificial intelligence promises to accelerate new discoveries, new therapies and new hope for patients."_ JOANNA SHIELDS — CEO, BenevolentAI Drug programmes careers COVID-19 Data Diversity initiativeContact us
Company Registration: 09781806Terms & Conditions
Privacy & Cookies PolicyDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0